Autologous Platelet-Derived Growth Factors (Platelet-Rich Plasma [PRP]) - (0507) — MM 0507 | CIGNA Coverage Update

TL;DR: Cigna Healthcare modified MM 0507 for platelet-rich plasma (PRP), effective October 16, 2025. Both primary billing codes — 0232T and G0460 — are classified as experimental/investigational/unproven. Here's what billing teams need to do.

Cigna Healthcare updated coverage policy MM 0507 governing autologous platelet-derived growth factors (APDGF), commonly known as platelet-rich plasma or PRP. This modification applies to CPT 0232T and HCPCS G0460, the two codes used to bill PRP injections and PRP products for wound care under Cigna plans. If your practice bills PRP for any indication — orthopedic, wound care, or otherwise — this policy directly affects your reimbursement and claim denial risk as of October 16, 2025.

Quick-Reference Table

Cigna Platelet-Rich Plasma Coverage Criteria and Medical Necessity Requirements 2025

The short version: Cigna does not consider PRP medically necessary for any indication covered under MM 0507. That's not a soft maybe. Both codes in this coverage policy — 0232T and G0460 — are classified as experimental, investigational, and unproven. That designation forecloses standard medical necessity arguments.

This matters because the experimental/investigational classification sits above the medical necessity threshold. You can document every clinical criterion correctly and still get denied. The payer's position is that the evidence base for PRP doesn't meet their standard for coverage — regardless of physician judgment or clinical guidelines from specialty societies.

The Cigna PRP coverage policy addresses autologous platelet-derived growth factors across multiple conditions and indications. The policy uses the umbrella term APDGF, which covers PRP in all its forms — injections at any site, image-guided procedures, and blood-derived products used in wound care. If a service involves harvesting, preparing, or injecting platelet-rich plasma, it falls under MM 0507.

Prior authorization won't rescue these claims. When a payer designates a procedure experimental/investigational, prior auth is typically irrelevant — and in some cases, getting a prior auth approval doesn't guarantee payment if the underlying coverage policy classifies the code as non-covered. Don't assume a prior authorization approval overrides the experimental designation in MM 0507. Verify at the plan level before you bill.

The practical effect: if your revenue cycle team has been billing 0232T or G0460 to Cigna and getting paid, check whether those payments came from specific plan-level carve-outs or administrative errors. Don't count on that continuing after October 16, 2025.

Cigna PRP Exclusions and Non-Covered Indications

MM 0507 doesn't carve out any specific PRP indication as covered. The policy applies the experimental/investigational/unproven designation broadly — across every proposed use of autologous platelet-derived growth factors.

That includes CPT 0232T, which covers PRP injections at any site, including image guidance, harvesting, and preparation. It also includes HCPCS G0460, the code for autologous platelet-rich plasma or other blood-derived products used for nondiabetic chronic wounds. Neither code has a covered pathway under this policy as written.

The policy specifically addresses "multiple conditions and indications." Cigna isn't singling out one application of PRP as problematic — they're drawing a line across the entire clinical category. This is similar to how Cigna and other major payers have approached genetic testing panels: the technology isn't the issue, the evidence standard is. PRP billing gets caught in that same evidence-based coverage framework.

Common indications that practices attempt to bill under 0232T include:

None of these have a covered pathway under MM 0507 for Cigna. The policy's scope is broad enough to capture them all.

Coverage Indications at a Glance

Cigna PRP Billing Guidelines and Action Items 2025

These are steps your billing team should take before and after the October 16, 2025 effective date.

CPT, HCPCS, and ICD-10 Codes for Platelet-Rich Plasma Under MM 0507

The policy data for MM 0507 lists two codes. Both carry the same coverage designation. There are no covered codes under this policy.

Not Covered / Experimental Codes

The MM 0507 policy data does not include ICD-10-CM diagnosis codes. Coverage status here is driven by procedure code, not diagnosis — the experimental designation applies regardless of the underlying condition being treated.

A note on 0232T: this is a Category III CPT code, which already signals emerging or experimental technology in the AMA code structure. Cigna's classification as experimental/investigational aligns with — and reinforces — the Category III status. Payers frequently use Category III codes as a gatekeeping mechanism, and Cigna is consistent with that approach here.

G0460 is a HCPCS Level II code used primarily in outpatient and wound care settings. Its inclusion under MM 0507 confirms that Cigna's experimental designation isn't limited to orthopedic or injection-based PRP applications. Wound care programs billing Cigna for any blood-derived PRP product are equally exposed to claim denial under this policy.